These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

966 related items for PubMed ID: 1331167

  • 1. Inhibition of ovulation by low-dose mifepristone (RU 486).
    Ledger WL, Sweeting VM, Hillier H, Baird DT.
    Hum Reprod; 1992 Aug; 7(7):945-50. PubMed ID: 1331167
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Late luteal phase administration of RU486 for three successive cycles does not disrupt bleeding patterns or ovulation.
    Croxatto HB, Salvatierra AM, Romero C, Spitz IM.
    J Clin Endocrinol Metab; 1987 Dec; 65(6):1272-7. PubMed ID: 3119656
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Interference with ovulation by sequential treatment with the antiprogesterone RU486 and synthetic progestin.
    Kekkonen R, Alfthan H, Haukkamaa M, Heikinheimo O, Luukkainen T, Lähteenmäki P.
    Fertil Steril; 1990 Apr; 53(4):747-50. PubMed ID: 2108063
    [Abstract] [Full Text] [Related]

  • 6. The effect of RU486 administered during the proliferative and secretory phase of the cycle on the bleeding pattern, hormonal parameters and the endometrium.
    Swahn ML, Johannisson E, Daniore V, de la Torre B, Bygdeman M.
    Hum Reprod; 1988 Oct; 3(7):915-21. PubMed ID: 2846630
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Early luteal phase treatment with mifepristone (RU 486) for fertility regulation.
    Gemzell-Danielsson K, Swahn ML, Svalander P, Bygdeman M.
    Hum Reprod; 1993 Jun; 8(6):870-3. PubMed ID: 8345076
    [Abstract] [Full Text] [Related]

  • 9. Effects of a sequential regimen of mifepristone-medroxyprogesterone acetate on ovarian function, endometrial development and hormonal parameters.
    Croxatto HB, Massai MR, Salvatierra AM, Fuentealba B, Croxatto HD, Lähteenmäki P.
    Contraception; 1996 Aug; 54(2):79-86. PubMed ID: 8842583
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Inhibition of ovulation by progestin analogs (agonists vs antagonists): preliminary evidence for different sites and mechanisms of actions.
    Heikinheimo O, Gordon K, Williams RF, Hodgen GD.
    Contraception; 1996 Jan; 53(1):55-64. PubMed ID: 8631191
    [Abstract] [Full Text] [Related]

  • 12. Onapristone (ZK 98.299): a potential antiprogestin for endometrial contraception.
    Katkam RR, Gopalkrishnan K, Chwalisz K, Schillinger E, Puri CP.
    Am J Obstet Gynecol; 1995 Sep; 173(3 Pt 1):779-87. PubMed ID: 7573244
    [Abstract] [Full Text] [Related]

  • 13. A comparative study on the return to ovulation following chronic use of once-a-month injectable contraceptives.
    Bassol S, Hernandez C, Nava MP, Trujillo AM, Luz de la Cruz D.
    Contraception; 1995 May; 51(5):307-11. PubMed ID: 7628206
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effect of mifepristone (RU486) on the pituitary response to gonadotrophin releasing hormone in women.
    Kazem R, Messinis LE, Fowler P, Groome NP, Knight PG, Templeton AA.
    Hum Reprod; 1996 Dec; 11(12):2585-90. PubMed ID: 9021355
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Variable effects of RU 486 on endometrial maintenance in the luteal phase extended by exogenous hCG.
    Croxatto HB, Salvatierra AM, Croxatto HD, Spitz IM.
    Clin Endocrinol (Oxf); 1989 Jul; 31(1):15-23. PubMed ID: 2598478
    [Abstract] [Full Text] [Related]

  • 19. Postpartum return of ovarian activity in nonbreastfeeding women monitored by urinary assays.
    Gray RH, Campbell OM, Zacur HA, Labbok MH, MacRae SL.
    J Clin Endocrinol Metab; 1987 Apr; 64(4):645-50. PubMed ID: 3818896
    [Abstract] [Full Text] [Related]

  • 20. Monitoring of ovarian activity by daily measurement of urinary excretion rates of oestrone glucuronide and pregnanediol glucuronide using the Ovarian Monitor, Part III: variability of normal menstrual cycle profiles.
    Blackwell LF, Vigil P, Cooke DG, d'Arcangues C, Brown JB.
    Hum Reprod; 2013 Dec; 28(12):3306-15. PubMed ID: 24170744
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.